Slideshow
Author(s):
OI may serve for research purposes as a simple and inexpensive indicator of evolving AD pathology. Details here.
Optimizing Parkinson Disease Care With Newly Approved Continuous Infusion Therapy
Episode 132: Aiding Diagnosis of Synucleinopathies Through SAAmplify-aSYN Biomarker Test
New Investigator-Initiated Study to Test CYR-064 for Hyposmia in Parkinson Disease
Neurology Unwrapped: 2024’s Most Intriguing Conversations
Insights on the Newly Approved Subcutaneous Infusion Therapy for Parkinson Disease
NeuroVoices: Sushma Kola, MD, on Integrative Approaches and Research Developments for Neurology Care in 2025